Targeting Drp1 inhibits ESCC progression via the ROS-PGC1-α-Nrf1/2 pathway
These findings uncover that Drp1 overexpression drived the growth and metastasis of ESCC via ROS-PGC1-α-Nrf1/2 signaling pathway, while miR-203a-3p significantly inhibited Drp1 expression and its capacity to mediate the malignant progression of ESCC cells. Our results provide potential novel therapeutic targets for the treatment of ESCC.
Authors
- Jiahui Zhou (ORCID: https://orcid.org/0000-0001-8509-5720)
- Yaxin Xue (ORCID: https://orcid.org/0000-0001-9516-286X)
- Dengke Bao (ORCID: https://orcid.org/0000-0002-6503-934X)
- Lixin Wan (ORCID: https://orcid.org/0000-0002-9759-5113)
- Xin Li (ORCID: https://orcid.org/0000-0002-7414-5734)
- Yu‐Dong Cai (ORCID: https://orcid.org/0000-0001-5664-7979)
- Mengyu Li (ORCID: https://orcid.org/0000-0001-9327-434X)
- Xiangyi Yu
- Mingjun Jiang (ORCID: https://orcid.org/0000-0001-8689-0662)
- Pei Han (ORCID: https://orcid.org/0000-0002-3422-3806)
- Yating Yang (ORCID: https://orcid.org/0000-0003-4671-8061)
- Congrong Liu (ORCID: https://orcid.org/0000-0002-9876-1603)
- Huizhen Wang
- Jing Zhao (ORCID: https://orcid.org/0000-0003-0764-8179)
- Zhixiong Jiang
- Qingqing Meng (ORCID: https://orcid.org/0009-0004-8125-2468)
Institutions
- Henan University (CN)
- Zhumadian Central Hospital (CN)
- Henan University of Engineering (CN)
- Nanyang Institute of Technology (CN)
- Shenyang 242 Hospital (CN)
- First Affiliated Hospital of Henan University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1186/s12967-025-06697-8
- Citations
- 2
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hainan Province
- Natural Science Foundation of Henan Province